Details:
Under the agreement, Evotec will be responsible for the discovery of drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or Evotec. Lilly reserves the right to select upto five programmes developed within this partnership.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2022